Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Ciduvectamig Biologics Sequence Review Report 2026: TMEFF2 × CD3E Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ciduvectamig, an antibody targeting TMEFF2 × CD3E.
Read →
Latest Hotspot
8 min read
Uprevstobart Biologics Sequence Review Report 2026: CD73 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Uprevstobart, an antibody targeting CD73.
Read →
Latest Hotspot
8 min read
Solrikitug Biologics Sequence Review Report 2026: TSLP Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Solrikitug, an antibody targeting TSLP.
Read →
Latest Hotspot
8 min read
Samatatug Biologics Sequence Review Report 2026: Tissue factor Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Samatatug, an antibody targeting Tissue factor.
Read →
Latest Hotspot
8 min read
Rezetamig Biologics Sequence Review Report 2026: CD3 × CD22 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rezetamig, an antibody targeting CD3 × CD22.
Read →
Latest Hotspot
8 min read
Opelkibart Biologics Sequence Review Report 2026: KIT Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Opelkibart, an antibody targeting KIT.
Read →
Latest Hotspot
8 min read
Linclatamig Biologics Sequence Review Report 2026: LY6G6D × CD3E Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Linclatamig, an antibody targeting LY6G6D × CD3E.
Read →
Latest Hotspot
8 min read
Enristomig Biologics Sequence Review Report 2026: PD-L1 × 4-1BB Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enristomig, an antibody targeting PD-L1 × 4-1BB.
Read →
Latest Hotspot
8 min read
Donitabart Biologics Sequence Review Report 2026: Ganglioside GD2 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Donitabart, an antibody targeting Ganglioside GD2.
Read →
Latest Hotspot
8 min read
Denikitug Biologics Sequence Review Report 2026: CCR8 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Denikitug, an antibody targeting CCR8.
Read →
Latest Hotspot
8 min read
Azirkitug Biologics Sequence Review Report 2026: CCR8 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Azirkitug, an antibody targeting CCR8.
Read →
Latest Hotspot
8 min read
Alextatug Biologics Sequence Review Report 2026: RNP complex containing PABPC1 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Alextatug, an antibody targeting RNP complex containing PABPC1.
Read →
<
1
<<
1147
1148
1149
1150
1151
>>
2260
>